Cencora, Inc. Monthly Stock Report - January 02, 2026

Company Overview

Cencora, Inc., headquartered in Conshohocken, Pennsylvania, is a leading entity within the medical distribution industry of the healthcare sector. The company specializes in sourcing and distributing pharmaceutical products both domestically and internationally. Cencora operates through two main segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. segment offers a comprehensive suite of services, including the distribution of generic and injectable pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies. Additionally, it provides pharmacy management, clinical trial support, and data analytics for biotech manufacturers.

Cencora's international operations focus on wholesale and logistics services, catering to pharmacies, health centers, and hospitals globally. As a former subsidiary of AmerisourceBergen Corporation, Cencora has a deep-rooted history in the industry, tracing back to 1871. With a commanding presence in a market that generates approximately $321.3 billion in total revenue, Cencora plays a pivotal role in ensuring the availability of essential healthcare supplies, making it an attractive option for investors looking for stability and growth in the healthcare sector.

52-Week Price Performance Analysis

52-Week Price Performance Chart

The stock performance for Cencora, Inc. (COR) over the past year showcases a predominantly bullish trend, with the price increasing significantly from around $225 at the beginning of the year to a high of approximately $377.54. Currently, the stock trades at $337.75, reflecting a robust 48.50% increase from its 52-week low of $223.92.

Key Technical Insights

• Resistance Levels: The price has encountered resistance near the $375 level, where it faced pullbacks. Monitoring this level will be crucial for identifying potential breakout opportunities.

• Support Levels: A significant support level is established around $300. The stock has maintained a position above this level, indicating strong purchasing interest in this range.

• Moving Averages: The 50-day moving average is currently positioned at $348.225, positioned above the current stock price, suggesting a potential bearish trend if the stock does not reclaim this level.

• Trend Analysis: The stock's price action portrays a series of higher highs and higher lows, solidifying a long-term uptrend. However, recent volatility hints at a retracement and possible consolidation phase, which retail investors should watch closely.

Overall, the technical landscape suggests that Cencora, Inc. has demonstrated considerable resilience, but caution is warranted as the stock nears established resistance points.

Financial Performance and Metrics

Cencora, Inc. exhibits strong financial performance metrics that enhance its standing as a viable investment:

• Total Revenue: The company reported impressive revenues exceeding $321 billion, signifying its vast operational scale and market presence.

• EBITDA: The EBITDA stands at approximately $4.81 billion, highlighting solid earnings capacity, effective management of operational expenses, and profitability.

• Shares Outstanding: Cencora has a total of 193,993,444 shares outstanding. With 4,876,600 shares sold short, the short interest represents about 4.32% of the company's float. This relatively low short percent of float indicates a cautious sentiment among investors regarding potential declines.

• Price Targets: Analysts are optimistic about Cencora's stock, setting a target price range with a high at $420.00, a mean at about $387.93, and a low at $315.00. This data suggests considerable growth potential, positioning Cencora favorably within the medical distribution space.

Recent News and Developments

Recent developments have significantly impacted Cencora's stock performance and market perception:

• Acquisition of OneOncology: On December 15, 2025, Cencora announced its intention to acquire the remaining stake in OneOncology, a strategic move anticipated to be earnings-neutral in the short term but expected to bring positive contributions by mid-fiscal year 2027. Analysts responded positively, with Evercore ISI raising its price target to $420 from $400 while maintaining an "Outperform" rating.

• All-Time High Achievements: In November 2025, Cencora's stock soared to an all-time high of $368.08, reflecting a remarkable 51.39% increase over the past year and a 63.64% year-to-date return, underscoring strong investor confidence.

• Price Target Adjustments: TD Cowen also raised its price target for Cencora to $400 from $350, citing a robust growth outlook and affirming a "Buy" rating.

• Legal Challenges: However, the company's recent past is marred by legal challenges, including a $111 million settlement in August 2025 related to its directors' failure to adequately address the company's involvement in the opioid crisis. This legal burden adds an element of risk to shareholders, demanding close scrutiny.

Market Sentiment and Analyst Recommendations

The market sentiment surrounding Cencora, Inc. appears cautiously optimistic, reflecting a balance of growth potential against ongoing legal challenges:

• Analyst Consensus: The stock currently holds a mean price target of approximately $387.93 based on insights from 15 analysts. Although there is no specific recommendation key available, the overall outlook remains positive due to recent upticks in price targets and estimates.

• Price Movements: Currently trading at $337.75, the stock's price remains below its fifty-day moving average of $348.225, indicating that investors should remain vigilant during potential corrections and the need for a price recovery.

• Investment Risks: Prospective investors should be aware of ongoing legal challenges and the volatility that has characterized the stock's recent performance. However, the current valuations against projected targets and firm fundamentals might present attractive long-term opportunities.

In conclusion, as Cencora, Inc. solidifies its place within the medical distribution sector, investors would benefit from maintaining awareness of market conditions and emerging opportunities. With strategic acquisitions underway, burgeoning revenue streams, and favorable growth projections, Cencora stands as an appealing candidate for those looking to invest in the healthcare space amidst the complexities of market dynamics.